Carbon ion radiotherapy for unresectable sacral chordomas

Carbon ion radiotherapy for unresectable sacral chordomas
复制标题

DOI:
10.1158/1078-0432.ccr-04-0301
复制
发表时间:
2004-09-01
影响因子:
11.5
通讯作者:
Tatezaki, S
Tatezaki, S
中科院分区:
医学1区
文献类型:
--
作者:
Imai, R;Kamada, T;Tatezaki, S

文献摘要

被引文献

相似文献

目的:目的是评估的疗效和毒性的碳离子放射治疗不可切除的骶骨脊索瘤。实验设计:我们进行了一项回顾性分析30例不可切除的骶骨脊索瘤治疗与碳离子放射治疗的重离子医用加速器在日本千叶。23例患者既往未接受治疗,其余7例患者在既往手术切除后局部复发。中位临床靶体积为546 cm(3)。应用的碳离子剂量范围从52.8到73.6 GyE(灰色当量,中位数70.4)在16个固定的分数超过4 weeks.Results:在中位数随访30个月(范围,9至87个月),26例患者仍然活着,24例患者仍然连续无病。5年的总体和病因特异性生存率分别为52%和94%。5年时局部控制率为96%。2例患者出现严重皮肤/软组织并发症,需要植皮。未进行其他治疗相关的手术干预,包括结肠造口术或尿流改道。所有患者都保持步行,并能够留在家里后,碳离子radiotherapy.Conclusions:碳离子放射治疗是有效和安全的管理与不可切除的骶骨脊索瘤的患者,并提供了一个有前途的替代手术。
Purpose: The purpose is to evaluate the efficacy and toxicity of carbon ion radiotherapy for unresectable sacral chordomas.Experimental Design: We performed a retrospective analysis of 30 patients with unresectable sacral chordomas treated with carbon ion radiotherapy at the Heavy Ion Medical Accelerator in Chiba, Japan. Twenty-three patients presented with no prior treatment, and the remaining 7 patients had locally recurrent disease following previous surgical resection. The median clinical target volume was 546 cm(3). The applied carbon ion dose ranged from 52.8 to 73.6 GyE (gray equivalent, median 70.4) in 16 fixed fractions over 4 weeks.Results: At median follow-up of 30 months (range, 9 to 87 months), 26 patients were still alive and 24 patients remained continuously disease-free. Overall and cause-specific survival rates at 5 years were 52 and 94%, respectively. The overall local control rate at 5years was 96%. Two patients experienced severe skin/soft tissue complications requiring skin grafts. No other treatment-related surgical interventions, including colostomy or urinary diversion, were carried out. All patients have remained ambulatory and able to stay at home after carbon ion radiotherapy.Conclusions: Carbon ion radiotherapy is effective and safe in the management of patients with unresectable sacral chordomas and offers a promising alternative to surgery.